title: Challenges in the development of a survivin vaccine (SurVaxM) for malignant glioma.
abstract: There is growing interest in immunotherapy for malignant gliomas. This interest stems from a number of immunological observations, together with the failure of conventional therapeutic agents to produce broad and clinically meaningful improvements in survival and quality of life. The challenges faced in translating laboratory-based immunological observations to Phase I and II clinical trials for immunotherapy of gliomas are substantial. Nevertheless, as our understanding of the effects of active specific vaccination in glioma patients grows, results support optimism that such methods may eventually prove useful as an adjunctive treatment for these cancers. This paper highlights a number of barriers encountered in the translational development of a survivin-targeted peptide vaccine (SurVaxM) for patients with malignant gliomas.
authors: Department of Neurosurgery, Roswell Park Cancer Institute and State University of New York School of Medicine and Biomedical Sciences, Elm and Carlton Streets, Buffalo, NY 14263, USA.
authors: Robert A
authors: RA
authors: Fenstermaker
authors: Michael J
authors: MJ
authors: Ciesielski
mesh_terms: D000912:Antibodies, Neoplasm / Q000276:immunology; D000951:Antigens, Neoplasm / Q000276:immunology*; D001932:Brain Neoplasms / Q000276:immunology / Q000517:prevention & control*; D019496:Cancer Vaccines / Q000276:immunology*; D005910:Glioma / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D051034:Inhibitor of Apoptosis Proteins / Q000276:immunology*; D000077022:Survivin; D014611:Vaccination
chemical_list: D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; C107489:BIRC5 protein, human; D019496:Cancer Vaccines; D051034:Inhibitor of Apoptosis Proteins; D000077022:Survivin